Yahoo Finance • last year

15 Best Falling Stocks To Buy Now

In this article, we will take a detailed look at the15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive not... Full story

Yahoo Finance • last year

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the C... Full story

Yahoo Finance • last year

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CEL... Full story

Yahoo Finance • last year

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today ann... Full story

Yahoo Finance • last year

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy Agreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2... Full story

Yahoo Finance • last year

(SPAC) Special Purpose Acquisition Investigation: FFIE, NRGV, CELU, Contact Shareholder Rights Law Firm Johnson Fistel

SAN DIEGO, July 12, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Faraday Future I... Full story

Yahoo Finance • last year

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company... Full story

Yahoo Finance • 2 years ago

Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products

Celularity has been advised by the Tamer Group to expect at least $60 million to $80 million in 2023 purchase orders for Celularity's branded Halal-Certified biomaterial products Tamer Group is the exclusive distributor of Celularity's br... Full story

Yahoo Finance • 2 years ago

Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy

FLORHAM PARK, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that Adrian Kilc... Full story

Yahoo Finance • 2 years ago

Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia

In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, two of four patients achieved an objective response at Day 28 In patients with mea... Full story

Yahoo Finance • 2 years ago

Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the Amer... Full story

Yahoo Finance • 2 years ago

Celularity Inc. Announces $6 Million Registered Direct Offering

FLORHAM PARK, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has en... Full story

Yahoo Finance • 2 years ago

Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and po... Full story

Yahoo Finance • 2 years ago

Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health

Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of the product Celularity intends to submit 510(k) pre-market notification to the FDA Center for Devices and Ra... Full story

Yahoo Finance • 2 years ago

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt

AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt Product distribution agreement opens access to Celularity’s Halal... Full story

Yahoo Finance • 2 years ago

Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)

Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix Celularity to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH)... Full story

Yahoo Finance • 2 years ago

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)

Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix Celularity to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) FL... Full story

Yahoo Finance • 2 years ago

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach FLORHAM PARK, N... Full story

Yahoo Finance • 2 years ago

Celularity Appoints Paul Graves as Chief Communications Officer

FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has bee... Full story

Yahoo Finance • 2 years ago

Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting

SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company devel... Full story